Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
kPQqcDsS0ZnRdNhy
Listen
